Apply for Amicar (Aminocaproic Acid) Copay Assistance

Amicar (aminocaproic acid) is an FDA-approved antifibrinolytic medication used to enhance hemostasis when fibrinolysis contributes to excessive bleeding. FDA-labeled indications include bleeding associated with cardiac surgery, hematologic disorders, neoplastic disorders, abruptio placentae, hepatic cirrhosis, and urinary fibrinolysis. Common off-label uses include mouth and mucosal bleeding in patients with hemophilia or von Willebrand disease, perioperative blood loss prevention in cardiac and spinal surgery, refractory bleeding during ECMO, and severe thrombocytopenia. Amicar is also known as epsilon-aminocaproic acid (EACA).

Cash prices for Amicar vary significantly based on dosage form, quantity, and pharmacy. Based on published 2026 average wholesale prices, oral aminocaproic acid 500 mg tablets range from approximately $7 to $32 per tablet, and 1000 mg tablets range from approximately $14 to $49 per tablet. Oral solution and IV solution are also available. Actual patient out-of-pocket cost is determined by your insurance plan, deductible, and any assistance programs applied. QuickRx patient navigators can help uninsured patients explore patient assistance programs, foundation grants, and other savings pathways. For real-time cash prices, check GoodRx or Drugs.com. Call (917) 830-2525 for a benefits review.

Yes. Generic aminocaproic acid is FDA-approved and widely available in the United States in all dosage forms — oral tablets (500 mg and 1000 mg), oral solution (25%), and intravenous solution (250 mg/mL). According to the FDA, the brand-name Amicar oral tablets and solution have been listed as discontinued products [DSC], so most patients today are dispensed generic aminocaproic acid. Generic and brand-name aminocaproic acid contain the same active ingredient and produce the same clinical effect.

Yes. QuickRx is a URAC-certified specialty pharmacy licensed in all 50 states, and we dispense Amicar (brand and generic aminocaproic acid) for patients with bleeding disorders, perioperative bleeding management needs, and other conditions requiring antifibrinolytic therapy. In 2025, our patient navigator team secured over $65 million in copay savings, grants, and patient assistance for the patients we serve. We ship nationwide with dedicated patient navigator support. Call (917) 830-2525 to transfer your prescription.

Call QuickRx at (917) 830-2525 or complete the short form on this page. A patient navigator will verify your insurance benefits, confirm your eligibility for any active manufacturer copay programs, patient assistance programs, or foundation grants, and handle all enrollment paperwork at no cost to you.

A copay savings card is a manufacturer-sponsored or third-party program that may significantly reduce out-of-pocket costs for commercially insured patients who meet eligibility requirements. Because aminocaproic acid is now primarily dispensed as a generic, the specific copay card programs available change based on the dispensing manufacturer and your insurance plan. QuickRx patient navigators confirm current program terms at the time of enrollment and identify the best savings pathway for each patient.

No. Patients enrolled in Medicare, Medicaid, Tricare, VA, or any other federal or state healthcare program are not eligible for manufacturer copay cards due to federal anti-kickback regulations. However, other options may be available — including manufacturer patient assistance programs for eligible uninsured patients, independent foundation grants (such as the National Bleeding Disorders Foundation and Hemophilia Federation of America patient support funds), Medicare Extra Help (Low-Income Subsidy), and state pharmaceutical assistance programs. Our patient navigators can identify all available options at no cost.

A patient assistance program (PAP) provides medication at no cost to eligible uninsured patients who meet income and clinical criteria. Eligibility requirements typically include U.S. residency, no prescription insurance coverage, and household income below a defined threshold. Because aminocaproic acid is now primarily generic, available PAPs depend on the specific manufacturer dispensed. QuickRx patient navigators handle the application process on your behalf and identify the right PAP for your situation.

Yes. Independent charitable foundations periodically offer grants to help eligible patients with out-of-pocket costs for medications used in bleeding disorders, including aminocaproic acid. Organizations such as the National Bleeding Disorders Foundation, the Hemophilia Federation of America, the PAN Foundation, and HealthWell Foundation may offer grant funding for medication costs, copays, and related expenses depending on diagnosis and current fund availability. Availability, eligibility criteria, and funding levels change frequently — sometimes funds open and close within a single day. QuickRx patient navigators monitor open funds and apply on your behalf when you qualify.

Most copay card enrollments are processed the same day once your eligibility is confirmed. Patient assistance program applications and foundation grant applications take longer and vary by program — typically a few business days to a few weeks depending on the program and documentation required. Prior authorizations (if required by your insurance) typically take 24–72 hours. Our team keeps you informed at every step.

QuickRx dispenses generic aminocaproic acid in all FDA-approved dosage forms: oral tablets in 500 mg and 1000 mg strengths, oral solution 25% (250 mg/mL), and intravenous solution 250 mg/mL. Your prescriber will determine the correct strength, dosage form, and duration based on your diagnosis and individual clinical needs.

Yes. Call us at (917) 830-2525 and provide your current pharmacy’s name and phone number. Our team will contact your pharmacy directly, transfer the prescription, verify your benefits, and coordinate copay assistance enrollment — all in a single call.

Yes. QuickRx is licensed in all 50 states and ships Amicar (aminocaproic acid) nationwide with discreet packaging and temperature-controlled handling where appropriate. Standard and expedited shipping options are available. Call (917) 830-2525 for shipping details in your state.

Don’t give up — there are often multiple pathways to savings. If you’ve been denied a manufacturer copay card, our patient navigators will review alternative options including patient assistance programs, independent foundation grants, state pharmaceutical assistance programs, Medicare Extra Help, and clinical-trial-based access programs where applicable. Call (917) 830-2525 for a full financial review.

Many commercial and government insurance plans require prior authorization for aminocaproic acid, particularly for longer durations of therapy or higher dosage strengths. QuickRx patient navigators coordinate directly with your prescriber’s office to gather and submit the required clinical documentation — including diagnosis, treatment history, and supporting labs where applicable. Call (917) 830-2525 to start the process.

A copay card reduces out-of-pocket costs for patients with commercial prescription insurance. A patient assistance program (PAP) provides medication at no cost to eligible uninsured patients. The two programs serve different populations — commercially insured patients use the copay card, while uninsured patients who meet income criteria may qualify for the patient assistance program. Medicare and Medicaid patients are not eligible for manufacturer copay cards but may qualify for the patient assistance program, foundation grants, Medicare Extra Help, or other government programs.

Aminocaproic acid is an antifibrinolytic agent. It works by binding competitively to plasminogen, blocking its conversion to plasmin — the enzyme responsible for breaking down fibrin blood clots (a process called fibrinolysis). By inhibiting fibrinolysis, aminocaproic acid stabilizes existing blood clots and helps the body control bleeding. It is not a blood thinner and does not form new clots; instead, it preserves the clots the body has already made.